AU2009206753B2 - Protopanaxadiol-type ginsenoside compositions and uses thereof - Google Patents

Protopanaxadiol-type ginsenoside compositions and uses thereof Download PDF

Info

Publication number
AU2009206753B2
AU2009206753B2 AU2009206753A AU2009206753A AU2009206753B2 AU 2009206753 B2 AU2009206753 B2 AU 2009206753B2 AU 2009206753 A AU2009206753 A AU 2009206753A AU 2009206753 A AU2009206753 A AU 2009206753A AU 2009206753 B2 AU2009206753 B2 AU 2009206753B2
Authority
AU
Australia
Prior art keywords
subject
ginsenoside
composition
acetaldehyde
ethyl alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009206753A
Other languages
English (en)
Other versions
AU2009206753A1 (en
Inventor
Thomas E. Daley
Michael Tempesta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raptor Therapeutics Inc
Original Assignee
Raptor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raptor Therapeutics Inc filed Critical Raptor Therapeutics Inc
Publication of AU2009206753A1 publication Critical patent/AU2009206753A1/en
Application granted granted Critical
Publication of AU2009206753B2 publication Critical patent/AU2009206753B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2009206753A 2008-01-24 2009-01-23 Protopanaxadiol-type ginsenoside compositions and uses thereof Ceased AU2009206753B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2331008P 2008-01-24 2008-01-24
US61/023,310 2008-01-24
PCT/US2009/000431 WO2009094177A1 (en) 2008-01-24 2009-01-23 Protopanaxadiol-type ginsenoside compositions and uses thereof

Publications (2)

Publication Number Publication Date
AU2009206753A1 AU2009206753A1 (en) 2009-07-30
AU2009206753B2 true AU2009206753B2 (en) 2014-07-03

Family

ID=40578016

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009206753A Ceased AU2009206753B2 (en) 2008-01-24 2009-01-23 Protopanaxadiol-type ginsenoside compositions and uses thereof

Country Status (13)

Country Link
US (1) US8440632B2 (enExample)
EP (1) EP2254569B1 (enExample)
JP (1) JP5523348B2 (enExample)
KR (2) KR20160048228A (enExample)
CN (1) CN101977600B (enExample)
AU (1) AU2009206753B2 (enExample)
CA (1) CA2713104C (enExample)
DK (1) DK2254569T3 (enExample)
ES (1) ES2400491T3 (enExample)
MY (1) MY160074A (enExample)
NZ (1) NZ587134A (enExample)
TW (1) TWI440463B (enExample)
WO (1) WO2009094177A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5563285B2 (ja) * 2009-12-14 2014-07-30 ライオン株式会社 飲食品、医薬品、又は医薬部外品、並びに、プロトパナキサトリオールの安定化方法、及びプロトパナキサジオールの安定化方法
US20150087702A1 (en) * 2011-11-22 2015-03-26 The Johns Hopkins University Methods and compositions for reducing alcohol toxicity
KR101446743B1 (ko) * 2012-06-11 2014-10-01 한국생명공학연구원 실리마린을 유효성분으로 포함하는 알콜성 위궤양 예방 및 치료용 조성물
CN102727508B (zh) * 2012-07-15 2014-09-24 浙江大学 人参二醇皂苷组分制备及在防治帕金森氏病中的药物用途
US11338120B2 (en) 2012-08-29 2022-05-24 Palo Alto Investors LP Methods and devices for treating parasympathetic bias mediated conditions
WO2014178803A1 (en) * 2013-04-29 2014-11-06 Alkoçlar Erdal Can A composition for use in the treatment of alcohol addiction
KR101621356B1 (ko) * 2014-09-05 2016-05-17 한국과학기술원 진세노사이드 f2의 간 질환 예방 또는 치료 용도
BR112017008515B1 (pt) * 2014-10-28 2021-03-23 Robust Seed Technology A&F Aktiebolag Método aperfeiçoado para preparação de sementes
CN107635549A (zh) 2015-03-26 2018-01-26 杰奎琳·M·艾弗森 抑制与宿醉相关的症状的方法和组合物
KR101641477B1 (ko) * 2016-01-19 2016-07-20 이국진 홍삼 추출물을 이용한 커피나무의 재배방법
CN106511360A (zh) * 2016-12-02 2017-03-22 上海芮范生物科技有限公司 一种含有人参皂苷Rg3和水飞蓟素的组合物及药物
CN106619669B (zh) * 2016-12-02 2019-03-29 延边大学 原人参二醇皂苷在制备防治炎症疾病的药物中的应用
CN107441104B (zh) * 2017-08-24 2023-07-21 浙江大学 人参二醇皂苷Rb组分防治糖尿病并发症及代谢紊乱相关疾病的医药用途
KR102053208B1 (ko) * 2018-03-15 2019-12-06 숙명여자대학교 산학협력단 진세노사이드 Rb1 및 Rb2를 유효성분으로 함유하는 근육 재생용 조성물
KR102138252B1 (ko) * 2018-05-16 2020-07-29 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 효모의 nadph 관련 생합성 경로의 개량을 통한 진세노사이드 생산 증대
US11000537B2 (en) * 2018-10-17 2021-05-11 Amorepacific Corporation Composition comprising novel ginsenoside
US11000538B2 (en) * 2018-10-31 2021-05-11 Amorepacific Corporation Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside
KR102672902B1 (ko) * 2018-10-31 2024-06-10 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 숙취 해소용 조성물
CN109758464B (zh) * 2019-03-21 2019-10-25 淮阴师范学院 越南人参皂苷r4在制备神经退行性疾病治疗药物中的应用
AU2020363927A1 (en) 2019-10-10 2022-04-28 Zobrius Pharma As Improved anti-hangover composition, its preparation and uses
KR102654669B1 (ko) * 2021-06-30 2024-04-04 경희대학교 산학협력단 실리디아닌을 포함하는 인삼 금 나노에멀젼 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016362A1 (en) * 2003-08-18 2005-02-24 Yuyu Inc. A ginseng preparation using vinegar and process for thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1574806A (en) * 1976-06-03 1980-09-10 Inverni Della Beffa Spa Production of purified ginseng extracts and pharmaceutical compositions containing the extracts
US4966893A (en) 1989-01-13 1990-10-30 Pang Peter K T Method for treatment of senile dementia
JPH04316448A (ja) 1991-04-12 1992-11-06 Iwatani Internatl Corp 人参微粉末の製造方法
US5547671A (en) 1995-09-20 1996-08-20 Duthinh; Phu Anti-intoxication composition
JP3656972B2 (ja) * 1997-02-14 2005-06-08 丸善製薬株式会社 アルコール臭低減剤
US6083932A (en) 1997-04-18 2000-07-04 Cv Technologies Inc. Pharmaceutical compositions derived from ginseng and methods of treatment using same
US6156291A (en) 1997-08-28 2000-12-05 Cv Technologies Inc. Chemical and pharmacological standardization of herbal extracts
CN1630528A (zh) 1999-08-30 2005-06-22 独立行政法人科学技术振兴机构 含药用人参的脑细胞或神经细胞保护剂
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
CN1167424C (zh) 2000-11-18 2004-09-22 唐修文 三七人参皂甙肠溶片
US7011096B2 (en) * 2001-08-31 2006-03-14 Philip Morris Usa Inc. Oxidant/catalyst nanoparticles to reduce carbon monoxide in the mainstream smoke of a cigarette
US20030185910A1 (en) 2002-02-08 2003-10-02 Taik Koo Yun Cancer preventive composition comprising ginsenoside glycosides of red ginseng
US6936283B2 (en) 2003-07-25 2005-08-30 Langeland Bjoern T. Composition for stimulation of specific metallo-enzymes
US7186517B2 (en) * 2003-08-01 2007-03-06 Aesgen, Inc. Compositions and methods for monitoring breast cancer treatment
KR20050081247A (ko) 2004-02-12 2005-08-18 이처준 홍삼 및 흑삼을 이용한 해장국 제조 방법.
US20080021083A1 (en) 2004-03-03 2008-01-24 Daley Thomas E 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
KR100547253B1 (ko) 2004-05-29 2006-01-26 박명환 암 예방 및 치료에 유효한 진세노사이드 유도체
CN1698879B (zh) * 2005-06-21 2010-08-11 蔺益民 具有解酒护肝功能的产品及制备方法和用途
ATE554663T1 (de) * 2005-07-29 2012-05-15 Tima Foundation Zusammensetzung zur steuerung des alkohol metabolismus und zur reduktion des risikos von alkoholbedingten krankheiten

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016362A1 (en) * 2003-08-18 2005-02-24 Yuyu Inc. A ginseng preparation using vinegar and process for thereof

Also Published As

Publication number Publication date
US20110065659A1 (en) 2011-03-17
DK2254569T3 (da) 2013-02-25
US8440632B2 (en) 2013-05-14
AU2009206753A1 (en) 2009-07-30
TW200936144A (en) 2009-09-01
CA2713104C (en) 2016-07-12
KR101648987B1 (ko) 2016-08-17
TWI440463B (zh) 2014-06-11
HK1144772A1 (en) 2011-03-11
MY160074A (en) 2017-02-15
WO2009094177A1 (en) 2009-07-30
KR20100111300A (ko) 2010-10-14
EP2254569B1 (en) 2012-11-28
NZ587134A (en) 2012-04-27
JP5523348B2 (ja) 2014-06-18
CA2713104A1 (en) 2009-07-30
EP2254569A1 (en) 2010-12-01
CN101977600B (zh) 2013-02-27
JP2011510075A (ja) 2011-03-31
CN101977600A (zh) 2011-02-16
ES2400491T3 (es) 2013-04-10
KR20160048228A (ko) 2016-05-03

Similar Documents

Publication Publication Date Title
CA2713104C (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
US20260108485A1 (en) Compositions and methods for acutely raising nitic oxide levels
JP7473516B2 (ja) 腸の健康を促す組成物
US8372451B2 (en) Compositions and methods for treating depression
EP2800572B1 (en) Ellagitannins rich extracts composition
US12370165B2 (en) Hunger suppression
MX2011007842A (es) Tratamiento de trastornos mediados por factores neurotroficos.
JP4009642B2 (ja) 肥満改善用組成物
WO2006119038A1 (en) Compositions and methods for controlling glucose uptake
JP7569153B2 (ja) 経口皮膚バリア機能向上剤
EP4041269A1 (en) Improved anti-hangover composition, its preparation and uses
KR20210085011A (ko) 숙잠 및 효모 추출물을 유효성분으로 함유하는 숙취 해소용 조성물
US20150017203A1 (en) Combination product for treating excess weight and/or for improving the figure
HK1144772B (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
Fukami et al. Continuous ingestion of acetic acid bacteria: effect on cognitive function in healthy middle-aged and elderly persons
CN111773238A (zh) 用于治疗胰岛素抵抗综合征及2型糖尿病的中药制剂
EP3698786A2 (en) Hangover alleviating composition containing conjugate of sesamol and peptide as active ingredient
JP2009023948A (ja) ドーパミン抑制剤
JP2005200389A (ja) α−グルコシダーゼ阻害剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired